Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …

Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an
earlier phase 2 induction study, etrolizumab significantly improved clinical remission …

Acute cortisol changes are physiological indicators (ie, biomarkers) of psychosocial stress
that have been repeatedly assessed using standardized laboratory protocols like the Trier …

Background Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was
recently approved in the United States for the treatment of human immunodeficiency virus …

Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor
agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a …

Much progress has been made over the past decade with the development of novel
methods for addressing increasingly more complex multiplicity problems arising in …

Background Dolutegravir has been shown to be non-inferior to an integrase inhibitor and
superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI). In FLAMINGO, we …

Background & Aims Patients chronically infected with the hepatitis B virus rarely achieve
loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated …

Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a
previous phase 2 induction study, etrolizumab significantly improved clinical remission …

OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1
receptor agonist, with placebo and exenatide in type 2 diabetic patients. The primary …